Bulletin from Annual General Meeting of Diamyd Medical AB

The Annual General Meeting of Diamyd Medical AB (publ) was held on November 26,
2015.

The Company's income statement and balance sheet were adopted and the Board
members and the Chief Executive Officer were discharged from liability for the
2014/2015 fiscal year. The Annual General Meeting approved the Board's proposal
that no dividend be paid for the 2014/2015 fiscal year.

Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller,
Maria-Teresa Essen-Möller and Fredrik Åhlander were re-elected to the Board.

The Annual General Meeting approved the proposed remuneration to Board members
and the Chairman of the Board.

The Annual General Meeting resolved to re-elect the auditing company BDO until
the end of the Annual General Meeting 2016. Principal auditor is the authorized
public accountant Johan Pharmanson.

The Annual General Meeting resolved to authorize the Board, on one or more
occasions prior to the next Annual General Meeting to issue shares and to
deviate from the shareholders' preferential rights when so doing. Payment may be
made in cash, through a contribution or by offsetting. In a share issue for cash
payment and in deviation from the shareholders' preferential rights, the number
of shares issued pursuant to the authorization may not exceed 20 percent of the
shares in the Company when the share issue occurs.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through
pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy
(ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed
technologies for GABA and Gliadin have also potential to become key pieces of
the puzzle of a future solution to prevent, treat or cure autoimmune diabetes,
and also certain inflammatory diseases. At this time six clinical studies are
ongoing. Diamyd Medical is one of the major shareholders in the stem cell
company Cellaviva AB, which offers private family saving of stem cells in
umbilical cord blood. Stem cells can be expected to be used in Personalized
Regenerative Medicine (PRM), for example for restoration of beta cell mass in
diabetes patients where the autoimmune component of the disease has been
arrested by ABT.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the
ticker DMYD B.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.